Aripiprazole is metabolised by CYP3A4, which is strongly inhibited by the
protease inhibitors. Increased
aripiprazole levels are therefore expected.
Caution and monitoring are recommended. The manufacturers suggest that the dose of
aripiprazole should be halved.